Other Events ·
AstraZeneca, Daiichi Sankyo partner with Summit Therapeutics to evaluate Datroway combinations across multiple tumor types
AZNAstrazeneca PLC
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration agreement with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types, including lung and breast cancers. The partnership will initiate with a Phase III trial in first-line triple-negative breast cancer. Under the terms of the agreement, each company contributes its respective medicine and shares trial costs while retaining development and commercial rights to their own assets. This collaboration builds on AstraZeneca's recent equity investment in Summit Therapeutics, which supports clinical evaluations of ivonescimab combinations with various AstraZeneca oncology medicines. AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.